SCPS (SCPS) Stock Price & Analysis
SCPS (SCPS) rose 0.00% to USD 0 as of June 10, 2026 at 02:35 UTC, according to Nexqual real-time market data.
SCPS last closed at USD 0; the session ranged USD 0–0 on volume of 47,076 shares. Market capitalization is $25,250, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, June 10, 2026 at 02:35 UTC.
Key Statistics (as of June 10, 2026 at 02:35 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 47,076 shares |
| Market Cap | $25,250 |
| Exchange | PNK |
Technical Analysis (SCPS)
Nexqual's technical model rates SCPS "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:35 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.18 (neutral) |
| vs SMA50 | Above (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (SCPS)
Wall Street analysts rate SCPS "None", per Nexqual as of June 10, 2026 at 02:35 UTC.
| Consensus Rating | None |
|---|
Earnings (SCPS)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2021-09-30 | USD -0.08 vs est -0.23 ▲ beat |
| 2021-06-30 | USD -0.97 vs est -0.23 ▼ miss |
| 2021-03-31 | USD -0.22 vs est -0.08 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
Financials & Fundamentals (SCPS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.05 |
| Total Cash | $362,097 |
| Total Debt | $0 |
| Free Cash Flow | $490,408 |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
Financial Health Score (SCPS)
Nexqual rates SCPS's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:35 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $362K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$3M |
| Efficiency | Mixed — No data |
Ownership (SCPS)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 42.08M |
| Float | 34.22M |
| Short % of Float | +0.25% |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
Leadership (SCPS)
SCPS is led by Alan D. Horsager (age 51), President?of?Immuno-Oncology and President & CEO of Duet BioTherapeutics, per Nexqual as of June 10, 2026 at 02:35 UTC.
| President?of?Immuno-Oncology and President & CEO of Duet BioTherapeutics | Alan D. Horsager (age 51) |
|---|---|
| Senior Advisor & Director | Ira Scott Greenspan (age 66) |
| Vice Chairman, Secretary & Treasurer | Robert J. Gibson |
Major Backers & Investors (SCPS)
Notable institutional backers of SCPS include Fidelity, according to Nexqual as of June 10, 2026 at 02:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.01% |
Source: Nexqual, June 10, 2026 at 02:35 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WNW | Meiwu Technology Company Limite | USD 3.57 | ▲ 22.26% |
| GLSI | Greenwich LifeSciences, Inc. | USD 22.23 | ▼ 0.09% |
| VVOS | Vivos Therapeutics, Inc. | USD 0.7 | ▼ 19.08% |
| OCG | Oriental Culture Holding LTD | USD 1.91 | ▲ 12.35% |
| YGMZF | MingZhu Logistics Holdings Limi | USD 0 | ▲ 50% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:35 UTC. This page is informational and not investment advice.